

| | | |
|--|------------------------------------|-------------------------------|
| FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u> | ATTY. DOCKET NO. 0652.1710000 | APPLICATION NO. 09/077,214 |
| | APPLICANT SCHMIDT <i>et al.</i> | |
| | FILING DATE May 26, 1998 | GROUP To be assigned |

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB-CLASS | FILING DATE |
|------------------|----|-----------------|------|------|-------|-----------|-------------|
| | AA | | | | | | |
| | AB | | | | | | |
| | AC | | | | | | |
| | AD | | | | | | |
| | AE | | | | | | |
| | AF | | | | | | |
| | AG | | | | | | |
| | AH | | | | | | |
| | AI | | | | | | |
| | AJ | | | | | | |
| | AK | | | | | | |

FOREIGN PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB-CLASS | TRANSLATION |
|------------------|-----|-----------------|------------|---------|-------|-----------|--------------------|
| M31 | AL1 | WO 92/20356 ✓ | 11/26/1992 | WIPO WO | — | — | Yes No |
| M35 | AM1 | EP 0 569 678 ✓ | 11/18/1993 | Europe | — | — | Yes No |
| M21 | AN1 | WO 94/05304 ✓ | 03/17/1994 | WIPO WO | — | — | Yes No |
| M31 | AO1 | WO 94/21808 ✓ | 09/29/1994 | WIPO WO | — | — | Abstract Yes No |
| M31 | AP1 | WO 94/23031 ✓ | 10/13/1994 | WIPO WO | — | — | Yes No |

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

| | | | |
|-----|----|---|--|
| M21 | AR | 1 | Baskar, S., <i>et al.</i> , "MHC Class II-Transfected Tumor Cells Induce Long-Term Tumor-Specific Immunity in Autologous Mice," <i>Cell. Immunol.</i> 155:123-133 (April 1994). |
| M21 | AS | 1 | Dranoff, G., <i>et al.</i> , "Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity," <i>Proc. Natl. Acad. Sci. USA</i> 90:3539-3543 (April 1993). |
| M31 | AT | 1 | Dranoff, G., and Mulligan, R.C., "Gene Transfer as Cancer Therapy," <i>Adv. Immunol.</i> 58:417-454 (February 1995). |

EXAMINER



DATE CONSIDERED


8/10/2000

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

| | | |
|---|------------------------------------|-------------------------------|
| FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT | ATTY. DOCKET NO. 0652.1710000 | APPLICATION NO. 09/077,214 |
| | APPLICANT SCHMIDT <i>et al.</i> | |
| | FILING DATE May 26, 1998 | GROUP To be assigned |

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB-CLASS | FILING DATE |
|---------------------|----|-----------------|------|------|-------|-----------|-------------|
| | AA | | | | | | |
| | AB | | | | | | |
| | AC | | | | | | |
| | AD | | | | | | |
| | AE | | | | | | |
| | AF | | | | | | |
| | AG | | | | | | |
| | AH | | | | | | |
| | AI | | | | | | |
| | AJ | | | | | | |
| | AK | | | | | | |



FOREIGN PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB-CLASS | TRANSLATION |
|---------------------|-----|------------------------|------------|--------------------|-------|-----------|-------------|
| W3) | AL2 | WO 95/00159 | 01/05/1995 | WIPO WO | — | — | Yes No |
| | AM | | | | | | Yes No |
| | AN | | | | | | Yes No |
| | AO | | | | | | Yes No |
| | AP | | | | | | Yes No |

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

| | | | |
|----|----|---|--|
| W3 | AR | 2 | Kärre, K., <i>et al.</i> , "Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy," <i>Nature</i> 319:675-678 (February 1986). ✓ |
| W3 | AS | 2 | Mandelboim, O., <i>et al.</i> , "CTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma," <i>Nature</i> 369:67-71 (May 1994). ✓ |
| W | AT | 2 | Mandelboim, O., <i>et al.</i> , "Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides," <i>Nature Medicine</i> 1:1179-1183 (November 1995). ✓ |


| | |
|----------|---------------------------|
| EXAMINER | DATE CONSIDERED 8/10/2000 |
|----------|---------------------------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

| | | |
|---|------------------------------------|-------------------------------|
| FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT | ATTY. DOCKET NO. 0652.1710000 | APPLICATION NO. 09/077,214 |
| | APPLICANT SCHMIDT <i>et al.</i> | |
| | FILING DATE May 26, 1998 | GROUP To be assigned |

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB-CLASS | FILING DATE |
|---------------------|----|-----------------|------|------|-------|-----------|-------------|
| | AA | | | | | | |
| | AB | | | | | | |
| | AC | | | | | | |
| | AD | | | | | | |
| | AE | | | | | | |
| | AF | | | | | | |
| | AG | | | | | | |
| | AH | | | | | | |
| | AI | | | | | | |
| | AJ | | | | | | |
| | AK | | | | | | |



FOREIGN PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB-CLASS | TRANSLATION |
|---------------------|----|-----------------|------|---------|-------|-----------|-------------|
| | AL | | | | | | Yes No |
| | AM | | | | | | Yes No |
| | AN | | | | | | Yes No |
| | AO | | | | | | Yes No |
| | AP | | | | | | Yes No |

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

| | | | |
|----|----|---|---|
| | AR | 3 | Nabel, G.J., <i>et al.</i> , "Direct gene transfer with DNA-liposome complexes in melanoma: Expression, biologic activity, and lack of toxicity in humans," <i>Proc. Natl. Acad. Sci. USA</i> 90:11307-11311 (December 1993). |
| VB | AS | 3 | Oettgen, H.F., and Old, L.J., "Chapter 6. The History of Cancer Immunotherapy," in: <i>Biologic Therapy of Cancer</i> , DeVita, Jr., V.T., <i>et al.</i> , Eds., J.B. Lippincott Co., Philadelphia, pp. 87-119 (1991). |
| VB | AT | 3 | Ostrand-Rosenberg, S., "Tumor immunotherapy: the tumor cell as an antigen-presenting cell," <i>Curr. Opin. Immunol.</i> 6:722-727 (October 1994). |

| | |
|--------------------|-----------------|
| EXAMINER | DATE CONSIDERED |
| <i>[Signature]</i> | 8/10/2000 |

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

| | | | | | | | |
|--|--|--|--|------------------------------------|--|-------------------------------|--|
| FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u> | | | | ATTY. DOCKET NO. 0652.1710000 | | APPLICATION NO. 09/077,214 | |
| | | | | APPLICANT SCHMIDT <i>et al.</i> | | | |
| | | | | FILING DATE May 26, 1998 | | GROUP To be assigned | |

| U.S. PATENT DOCUMENTS | | | | | | | |
|-----------------------|----|-----------------|------|------|-------|-----------|-------------|
| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB-CLASS | FILING DATE |
| | AA | | | | | | |
| | AB | | | | | | |
| | AC | | | | | | |
| | AD | | | | | | |
| | AE | | | | | | |
| | AF | | | | | | |
| | AG | | | | | | |
| | AH | | | | | | |
| | AI | | | | | | |
| | AJ | | | | | | |
| | AK | | | | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | | |
|--------------------------|----|-----------------|------|---------|-------|-----------|-------------|
| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB-CLASS | TRANSLATION |
| | AL | | | | | | Yes No |
| | AM | | | | | | Yes No |
| | AN | | | | | | Yes No |
| | AO | | | | | | Yes No |
| | AP | | | | | | Yes No |

| OTHER (Including Author, Title, Date, Pertinent Pages, etc.) | | | |
|--|----|---|---|
| <i>MB1</i> | AR | 4 | Pardoll, D.M., "Cancer vaccines," <i>Immunol. Today</i> 14(6):310-316 (1993). |
| <i>MB1</i> | AS | 4 | Plautz, G.E., <i>et al.</i> , "Immunotherapy of malignancy by <i>in vivo</i> gene transfer into tumors," <i>Proc. Natl. Acad. Sci. USA</i> 90:4645-4649 (May 1993). |
| <i>MB1</i> | AT | 4 | Schmidt, W., <i>et al.</i> , "Cancer vaccines: The interleukin 2 dosage effect," <i>Proc. Natl. Acad. Sci. USA</i> 92:4711-4714 (May 1995). |

| | |
|---------------------|----------------------------------|
| EXAMINER <i>MB1</i> | DATE CONSIDERED <i>2/10/2000</i> |
|---------------------|----------------------------------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

| | | |
|--|------------------------------------|-------------------------------|
| FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u> | ATTY. DOCKET NO. 0652.1710000 | APPLICATION NO. 09/077,214 |
| | APPLICANT SCHMIDT <i>et al.</i> | |
| | FILING DATE May 26, 1998 | GROUP To be assigned |

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB-CLASS | FILING DATE |
|---------------------|----|-----------------|------|------|-------|-----------|-------------|
| | AA | | | | | | |
| | AB | | | | | | |
| | AC | | | | | | |
| | AD | | | | | | |
| | AE | | | | | | |
| | AF | | | | | | |
| | AG | | | | | | |
| | AH | | | | | | |
| | AI | | | | | | |
| | AJ | | | | | | |
| | AK | | | | | | |

FOREIGN PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB-CLASS | TRANSLATION |
|---------------------|----|-----------------|------|---------|-------|-----------|-------------|
| | AL | | | | | | Yes No |
| | AM | | | | | | Yes No |
| | AN | | | | | | Yes No |
| | AO | | | | | | Yes No |
| | AP | | | | | | Yes No |

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

| | | | |
|--|----|---|--|
| | AR | 5 | Schmidt, W., <i>et al.</i> , "Transloading of tumor cells with foreign major histocompatibility complex class I peptide ligand: A novel general strategy for the generation of potent cancer vaccines," <i>Proc. Natl. Acad. Sci. USA</i> 93:9759-9763 (September 1996). |
| | AS | 5 | Van Pel, A., and Boon, T., "Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis," <i>Proc. Natl. Acad. Sci. USA</i> 79:4718-4722 (August 1982). |
| | AT | 5 | Zatloukal, K., <i>et al.</i> , "Somatic gene therapy for cancer: the utility of transferrin infection in generating 'tumor vaccines'," <i>Gene</i> 135:199-207 (1993). |

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

| | | |
|---|------------------------------------|-------------------------------|
| FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT | ATTY. DOCKET NO. 0652.1710000 | APPLICATION NO. 09/077,214 |
| | APPLICANT SCHMIDT <i>et al.</i> | |
| | FILING DATE May 26, 1998 | GROUP To be assigned |

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB-CLASS | FILING DATE |
|---------------------|----|-----------------|------|------|-------|-----------|-------------|
| | AA | | | | | | |
| | AB | | | | | | |
| | AC | | | | | | |
| | AD | | | | | | |
| | AE | | | | | | |
| | AF | | | | | | |
| | AG | | | | | | |
| | AH | | | | | | |
| | AI | | | | | | |
| | AJ | | | | | | |
| | AK | | | | | | |

FOREIGN PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB-CLASS | TRANSLATION |
|---------------------|----|-----------------|------|---------|-------|-----------|-------------|
| | AL | | | | | | Yes No |
| | AM | | | | | | Yes No |
| | AN | | | | | | Yes No |
| | AO | | | | | | Yes No |
| | AP | | | | | | Yes No |

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

| | | | |
|----|----|---|---|
| MB | AR | 6 | Zatloukal, K., <i>et al.</i> , "Elicitation of a Systemic and Protective Anti-Melanoma Immune Response by an IL-2-Based Vaccine," <i>J. Immunol.</i> 154:3406-3419 (April 1995). |
| MB | AS | 6 | Zier, K.S., and Gansbacher, B., "Tumour Cell Vaccines That Secrete Interleukin-2 (IL-2) and Interferony (IFN γ) are Recognised by T Cells While Resisting Destruction by Natural Killer (NK) Cells," <i>Eur. J. Cancer</i> 32A:1408-1412 (July 1996). |
| | AT | | |

| | |
|----------|---------------------------|
| EXAMINER | DATE CONSIDERED 8/10/2000 |
|----------|---------------------------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.